Related Experiment Video
Updated: Sep 9, 2025
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Synchronous Primary Early-Stage Non-Small Cell Lung Cancer: Trends in Management and Factors Associated With Improved
Whitney S Brandt1, Nikki E Rossetti1, Daniel B Eaton2
1Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.
Background:
Outcomes after multimodality curative-intent treatment of patients with synchronous primary early-stage I non-small cell lung cancer (SPELC) are inadequately understood.
Methods:
We performed a retrospective study using the Veterans Health Administration database of patients diagnosed with 2 stage I SPELC tumors who received treatment with either stereotactic body radiotherapy (SBRT) or surgery from 2006 to 2024. We evaluated use of SBRT and surgery as well as factors associated with overall survival (OS) and disease-free survival (DFS) by Cox proportional hazards models.
Results:
A total of 835 patients were included; 294 (35.2%) underwent SBRT-SBRT, 149 (17.8%) received SBRT-surgery, and 392 (47%) underwent surgery-surgery. Patients treated with SBRT had more comorbidities (P < .0001) and were older (P < .0001). Use of SBRT increased from <20% in 2008 to >60% of cases in 2024. The adjusted 5-year OS was 51.7% (SBRT-SBRT) vs 72% (SBRT-surgery) vs 66.7% (surgery-surgery; P < .0001). Multivariable analysis demonstrated that patients who underwent SBRT-SBRT had worse OS (hazard ratio, 1.71; 95% CI, 1.32-2.22), but those in the SBRT-surgery group and surgery-surgery group had similar OS. Adjusted 5-year DFS was 42.7% (SBRT-SBRT) vs 42.6% (surgery-SBRT) vs 57.26% (surgery-surgery). On multivariable analysis, DFS was inferior in the SBRT-SBRT group (hazard ratio, 1.525; 1.198-1.942; P = .0006) and SBRT-surgery group (hazard ratio, 1.530; 1.011-2.314; P = .04) than in the surgery-surgery group.
Conclusions:
In veterans with stage I SPELC, there is heterogeneity in outcomes based on treatment modality among other factors. Patients who are selected for surgery for both lesions have the best DFS but similar OS to those who undergo surgery-SBRT.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
01:21Cancer Survival Analysis
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:24Kaplan-Meier Approach